Skip to content

Study · Non-randomized trial · n = 521 · 2021

6 results

Benefit of insulin glargine/lixisenatide for reducing residual hyperglycaemia in Japan: Post hoc analysis of the LixiLan JP-O2 trial.

Iizuka K, Baxter M, Watanabe D, Yabe D

Diabetes, obesity & metabolism23 Sept 2021Cited by 3 (Europe PMC)

PMID34472693 (opens in a new tab)PMCIDPMC9293167 (opens in a new tab)DOI10.1111/dom.14537 (opens in a new tab)PepBankPUB-34472693
Read at sourcePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In Japanese adults with diabetes, residual hyperglycaemia occurred in 8.1% with iGlarLixi versus 19.6% with insulin glargine (P = .0002).

    In plain wordsIn Japanese adults with diabetes, residual high glucose was less frequent with added lixisenatide than insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    DecreaseResidual hyperglycaemia overall
    Study

    n = 521

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    Proportion
    8.1%
    residual hyperglycaemia, overall, week 26, iGlarLixi
    Proportion
    19.6%
    residual hyperglycaemia, overall, week 26, iGlar
    P value
    0.0002
    residual hyperglycaemia, overall, week 26

    Source sentences

    Summary
    At 26 weeks, significantly fewer participants had residual hyperglycaemia in the iGlarLixi versus the iGlar arm (8.1% vs. 19.6%; P = .0002).
    1 context sentence
    Summary · context
    The open-label LixiLan JP-O2 study compared iGlarLixi with iGlar over 26 weeks in 521 people with T2D.
  2. 02HumanNon-randomized trialEfficacy outcome

    In Japanese adults with diabetes, combined glucose targets were attained by 50.8% with iGlarLixi versus 31.5% with insulin glargine (P < .0001).

    In plain wordsIn Japanese adults with diabetes, more reached both glucose targets with added lixisenatide than insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    IncreaseCombined HbA1c and fasting glucose target overall
    Study

    n = 521

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    Proportion
    50.8%
    HbA1c <7% and FPG <130 mg/dL, overall, iGlarLixi
    Proportion
    31.5%
    HbA1c <7% and FPG <130 mg/dL, overall, iGlar
    P value
    < 0.0001
    HbA1c <7% and FPG <130 mg/dL, overall

    Source sentences

    Summary
    The proportion reaching both HbA1c less than 7% and FPG less than 130 mg/dL was higher with iGlarLixi versus iGlar in the overall population (50.8% vs. 31.5%; P < .0001), and in all studied subgroups.
    1 context sentence
    Summary · context
    The open-label LixiLan JP-O2 study compared iGlarLixi with iGlar over 26 weeks in 521 people with T2D.
  3. 03HumanNon-randomized trialEfficacy outcome

    In Japanese participants younger than 65 years, residual hyperglycaemia occurred in 9.0% with iGlarLixi versus 16.8% with insulin glargine (P = .0369).

    In plain wordsIn younger Japanese participants, residual high glucose was less frequent with added lixisenatide than insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    DecreaseResidual hyperglycaemia under age 65
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    Proportion
    9%
    residual hyperglycaemia, age <65 years, iGlarLixi
    Proportion
    16.8%
    residual hyperglycaemia, age <65 years, iGlar
    P value
    0.0369
    residual hyperglycaemia, age <65 years

    Source sentences

    Summary
    There was also less residual hyperglycaemia with iGlarLixi than iGlar in all subgroup analyses: 9.0% versus 16.8% in participants aged younger than 65 years (P = .0369);
    1 context sentence
    Summary · context
    The open-label LixiLan JP-O2 study compared iGlarLixi with iGlar over 26 weeks in 521 people with T2D.
  4. 04HumanNon-randomized trialEfficacy outcome

    In Japanese participants aged 65 years or older, residual hyperglycaemia occurred in 6.5% with iGlarLixi versus 24.2% with insulin glargine (P = .0008).

    In plain wordsIn older Japanese participants, residual high glucose was less frequent with added lixisenatide than insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    DecreaseResidual hyperglycaemia age 65 or older
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    Proportion
    6.5%
    residual hyperglycaemia, age >=65 years, iGlarLixi
    Proportion
    24.2%
    residual hyperglycaemia, age >=65 years, iGlar
    P value
    0.0008
    residual hyperglycaemia, age >=65 years

    Source sentences

    Summary
    6.5% versus 24.2% in participants aged 65 years or older (P = .0008);
    1 context sentence
    Summary · context
    The open-label LixiLan JP-O2 study compared iGlarLixi with iGlar over 26 weeks in 521 people with T2D.
  5. 05HumanNon-randomized trialEfficacy outcome

    In Japanese participants with DPP4i use, residual hyperglycaemia occurred in 10.1% with iGlarLixi versus 20.5% with insulin glargine (P = .0202).

    In plain wordsIn Japanese participants using DPP4i drugs, residual high glucose was less frequent with added lixisenatide than insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    DecreaseResidual hyperglycaemia with DPP4i use
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    Proportion
    10.1%
    residual hyperglycaemia, with DPP4i use, iGlarLixi
    Proportion
    20.5%
    residual hyperglycaemia, with DPP4i use, iGlar
    P value
    0.0202
    residual hyperglycaemia, with DPP4i use

    Source sentences

    Summary
    10.1% versus 20.5% (P = .0202) in participants with DPP4i use;
    1 context sentence
    Summary · context
    The open-label LixiLan JP-O2 study compared iGlarLixi with iGlar over 26 weeks in 521 people with T2D.
  6. 06HumanNon-randomized trialEfficacy outcome

    In Japanese participants without DPP4i use, residual hyperglycaemia occurred in 6.2% with iGlarLixi versus 18.8% with insulin glargine (P = .0024).

    In plain wordsIn Japanese participants without DPP4i use, residual high glucose was less frequent with added lixisenatide than insulin glargine alone.

    Peptide
    Lixisenatide
    Outcome
    DecreaseResidual hyperglycaemia without DPP4i use
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    Proportion
    6.2%
    residual hyperglycaemia, without DPP4i use, iGlarLixi
    Proportion
    18.8%
    residual hyperglycaemia, without DPP4i use, iGlar
    P value
    0.0024
    residual hyperglycaemia, without DPP4i use

    Source sentences

    Summary
    and 6.2% versus 18.8% in those without DPP4i use (P = .0024).
    1 context sentence
    Summary · context
    The open-label LixiLan JP-O2 study compared iGlarLixi with iGlar over 26 weeks in 521 people with T2D.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.